Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2012; 61: 816-819....
(redirected from pneumococcal heptavalent conjugate vaccine)Also found in: Thesaurus, Medical, Encyclopedia. vac·cine (văk-sēn′, văk′sēn′) n. 1. a. A preparation of a weakened or killed pathogen, such as a bacterium or virus, or of a portion of the pathogen's structure, ...
Pneumococcal 15-valent conjugate vaccine (PCV15; Vaxneuvance) or pneumococcal 20-valent conjugate vaccine (PCV20; Prevnar 20) for all children aged 2 through 23 months according to currently recommended PCV dosing and schedules; Children with an incomplete PCV vaccination status, use of either PC...
13-valent pneumococcal conjugate vaccine: a review of its use in adults. Drugs. 2015; 75(13): 1535-46.Greg L. Plosker. (2015) 13-Valent Pneumococcal Conjugate Vaccine: A Review of Its Use in Adults. Drugs 75 , 1535-1546 /Plosker, G.L., 2015. 13-Valent pneumococcal conjugate vaccine...
We performed a randomized, modified double-blind trial that compared a single dose of 13-valent pneumococcal conjugate vaccine (PCV13) with 23-valent pneumococcal polysaccharide vaccine (PPSV23) in 831 pneumococcal vaccine naive adults 60–64 years of age. An additional group of 403 adults 50–...
Cost-effectivenessElderlyPCV13PPV23PneumococcalPneumoniaBackground: The 23-valent pneumococcal polysaccharide vaccine (PPV23) has been funded under the Australia ... S Dirmesropian,JG Wood,CR Macintyre,... - 《Vaccine》 被引量: 7发表: 2017年 Effectiveness of the 23-valent polysaccharide pneumococca...
Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) (PCV13; Prevenar 13 ; Prevnar 13 ) is approved in adults aged ≥50years (focus of review) and in children aged 6weeks to 5years for protection against pneumococcal diseases caused by Streptococcus pneumoniae in numerous countries ...
20-Valent Pneumococcal Conjugate Vaccine (Prevenar 20) has the broadest serotype coverage of any paediatric pneumococcal conjugate vaccine, helping to protect against all 20 serotypes. PREVNAR 20 expands on PREVNAR 13® profile (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F...
Health care professionals can learn about VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) and PNEUMOVAX®23 (Pneumococcal Vaccine Polyvalent), as well as the indications for each.
Infants in the UK were first offered a pneumococcal conjugate vaccine (PCV7) in 2006, given at 2 and 4 months of age and a booster dose at 13 months (2 + 1 schedule). A 13-valent vaccine (PCV13) replaced PCV7 in 2010. We aimed to compare the post-booster antibody response in...